283 patents
Page 3 of 15
Utility
Compounds Useful As Inhibitors of Atr Kinase
31 Aug 23
Nadia AHMAD, Dean BOYALL, Jean-Damien CHARRIER, Chris DAVIS, Rebecca DAVIS, Steven DURRANT, Gorka ETXEBARRIA I JARDI, Damien FRAYSSE, Juan-Miguel JIMENEZ, David KAY, Ronald KNEGTEL, Donald MIDDLETON, Michael O'DONNELL, Maninder PANESAR, Francoise PIERARD, Joanne PINDER, David SHAW, Pierre-Henri STORCK, John STUDLEY, Heather TWIN
Filed: 23 Jun 22
Utility
Inhibitors of APOL1 and Methods of Using Same
31 Aug 23
The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
Jingrong CAO, Jon H. COME, Leslie A. DAKIN, Francois DENIS, Warren A. DORSCH, Anne FORTIER, Martine HAMEL, Elaine B. KRUEGER, Brian LEDFORD, Suganthini S. NANTHAKUMAR, Olivier NICOLAS, Camil SAYEGH, Timothy J. SENTER, Tiansheng WANG, Michael BRODNEY, Kan-Nian HU, Peter ROSE, Kevin GAGNON, Yi SHI, Muna SHRESTHA, Ales MEDEK, Faith WITKOS
Filed: 7 Feb 23
Utility
Solid Forms of APOL1 Inhibitor and Methods of Using Same
10 Aug 23
Kevin James GAGNON, Jicong LI, Ales MEDEK, Jack Raphael MINCHOM, Yi SHI, Muna SHRESTHA, Faith WITKOS
Filed: 11 Jun 21
Utility
Methods of Treatment for Cystic Fibrosis
3 Aug 23
Weichao George Chen, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz
Filed: 31 Aug 22
Utility
Modified Urokinase-type Plasminogen Activator Polypeptides and Methods of Use
3 Aug 23
Provided are nucleic acid molecules, including vectors and plasmids, encoding modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides.
Edwin L. MADISON, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
Filed: 10 Feb 23
Utility
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
27 Jul 23
Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
Filed: 14 Jul 22
Utility
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
25 Jul 23
Berenice Lemercier Lewandowski, Robert Lewis, Adam Looker, Adam Morgan, Stefanie Roeper, Michael Ryan, Juan Gabriel Solsona Rocabert, Nathan Wilde
Filed: 30 Nov 18
Utility
Materials and Methods for Treatment of Myotonic Dystrophy Type 1 (DM) and Other Related Disorders
20 Jul 23
The present application provides materials and methods for treating a patient with one or more conditions associated with DMPK whether ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 28 Jun 22
Utility
Stem Cell Derived Pancreatic Islet Differentiation
13 Jul 23
Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells.
George Harb, Chunhui Xie, Bryce W. Carey, Aleksander Szymaniak, Christopher Thanos, Evrett Thompson, Rebecca Chinn, Suyash Raj
Filed: 1 Nov 22
Utility
Pharmaceutical Composition and Administrations Thereof
6 Jul 23
The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D.J. Grootenhuis, Martyn Botfield, Alfredo Grossi
Filed: 30 Dec 22
Utility
Inhibitors of APOL1 and Methods of Using Same
29 Jun 23
Leslie A. DAKIN, Michael A. BRODNEY, Kevin B. DANIEL, Elena DOLGIKH, Pedro M. GARCIA BARRANTES, Ales MEDEK, Jessica H. OLSEN, Timothy J. SENTER, Akira J. SHIMIZU, Steven D. STONE, Charlene TSAY
Filed: 29 Nov 22
Utility
PYRANO[4,3-B]INDOLE Derivatives As ALPHA-1-ANTITRYPSIN Modulators for Treating ALPHA-1-ANTITRYPSIN Deficiency (Aatd)
25 May 23
Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)
Michael Philip CLARK, Simon GIROUX, Philip Noel COLLIER, Qing TANG, Nathan D. WAAL, Sarathy KESAVAN, Peter JONES, Michael Aaron BRODNEY, Wenxin GU, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, JR., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL
Filed: 2 Apr 21
Utility
7- or 8-HYDROXY-ISOQUINOLINE and 7- or 8-HYDROXY-QUINOLINE Derivatives As ALPHA-1-ANTITRYPSIN Modulators for Treating ALPHA-1-ANTITRYPSIN Deficiency (Aatd)
25 May 23
7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).
Simon GIROUX, Michael Philip CLARK, Michael Aaron BRODNEY, Peter JONES, Michael Paul DENINNO, Wenxin GU, Qing TANG, Steven David STONE, Timothy J. SENTER, Zachary GALE-DAY, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL
Filed: 2 Apr 21
Utility
1H-PYRAZOLO[4,3-G]ISOQUINOLINE and 1H-PYRAZOLO[4,3-G]QUINOLINE Derivatives As ALPHA-1-ANTITRYPSIN Modulators for Treating ALPHA-1-ANTITRYPSIN Deficiency (Aatd)
25 May 23
1H-pyrazolo[4,3-g]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).
Simon GIROUX, Philippe Marcel NUHANT, Upul Keerthi BANDARAGE, Pedro Manuel GARCIA BARRANTES, Yusheng LIAO, Zachary GALE-DAY, Wenxin GU, Alexander S. KARNS, Hu ZHANG, Emily Elizabeth ALLEN, Jinwang XU, Michael Paul DENINNO, Qing TANG, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL
Filed: 2 Apr 21
Utility
PYRROLO[2,3-F]INDAZOLE and 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE Derivatives As ALPHA-1-ANTITRYPSIN Modulators for Treating ALPHA-1-ANTITRYPSIN Deficiency (Aatd)
25 May 23
Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.03,7]dodeca-1,3(7),5,8,11-pentaene derivatives as alpha-l-antitrypsin modulators for treating alpha-l-antitrypsin deficiency (AATD)
Simon GIROUX, Michael John BOYD, Robert Francis FIMOGNARI, Jr., Mariam ZAKY, Ronald Lee GREY, Jr., Jinwang XU, Sarathy KESAVAN, Philippe Marcel NUHANT, Pedro Manuel GARCIA BARRANTES, Peter JONES, Michael Aaron BRODNEY, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL
Filed: 2 Apr 21
Utility
Indole Derivatives As ALPHA-1-ANTITRYPSIN Modulators for Treating ALPHA-1-ANTITRYPSIN Deficiency (Aatd)
25 May 23
Indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).
Simon GIROUX, Michael Philip CLARK, Michael Aaron BRODNEY, Philippe Marcel NUHANT, Emily Elizabeth ALLEN, Robert Francis FIMOGNARI, Jr., Mariam ZAKY, Michael John BOYD, David D. DEININGER, Hu ZHANG, Hongbo DENG, Philip Noel COLLIER, Brad MAXWELL, Nathan D. WAAL, Steven M. RONKIN, Jian WANG, Qing TANG, Gabrielle Simone FLEMING, Peter JONES, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL, Upul Keerthi BANDARAGE
Filed: 2 Apr 21
Utility
Antiproliferation Compounds and Uses Thereof
18 May 23
The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).
Henry YU, Michael Clark, Guy Bemis, Micheal Boyd, Kishan Chandupatla, Philip Collier, Hongbo Deng, Huijun Dong, Warren Dorsch, Russell R. Hoover, Mac Arthur Johnson, JR., Shashank Kulkarni, Marina Penney, Steven Ronkin, Darin Takemoto, Qing Tang, Nathan D. Waal, Tiansheng Wang, David J. Lauffer, Pan Li
Filed: 7 Sep 22
Utility
Methods of Enhancing Stem Cell Differentiation into Beta Cells
11 May 23
Disclosed herein are compositions and methods of enhancing stem cell differentiation into beta cells with use of one or more epigenetic modification compounds.
Felicia PAGLIUCA, George HARB, Mads GURTLER, Austin THIEL, Jihad YASIN, Evrett THOMPSON
Filed: 11 Nov 22
Utility
Methods of Enhancing Stem Cell Differentiation into Beta Cells
4 May 23
Disclosed herein are compositions and methods of enhancing stem cell differentiation into beta cells with use of one or more epigenetic modification compounds.
Felicia PAGLIUCA, George HARB, Mads GURTLER, Austin THIEL, Jihad YASIN, Evrett THOMPSON
Filed: 11 Nov 22
Utility
Modulators of ATP-binding cassette transporters
2 May 23
Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”).
Sara S. Hadida Ruah, Peter D. J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Jamel Numa, Xiaoqing Yang
Filed: 22 Feb 21